JP2002514187A - 薬剤としての置換γ―アミノ酪酸 - Google Patents
薬剤としての置換γ―アミノ酪酸Info
- Publication number
- JP2002514187A JP2002514187A JP51940498A JP51940498A JP2002514187A JP 2002514187 A JP2002514187 A JP 2002514187A JP 51940498 A JP51940498 A JP 51940498A JP 51940498 A JP51940498 A JP 51940498A JP 2002514187 A JP2002514187 A JP 2002514187A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- aminomethyl
- effective amount
- therapeutically effective
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heat Sensitive Colour Forming Recording (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式I を有する化合物またはそれらの製薬上許容しうる塩。 上記式中、 Rは水素または低級アルキルであり; R1は水素または低級アルキルであり; は分枝状アルキル、−(CH2)(1-4)-X-(CH2)(0-4)−フェニルであり、Xは-O-、 -S-、-NR3-であり、R3は1〜6個の炭素のアルキル、3〜8個の炭素のシクロア ルキル、ベンジル、フェニルであり、ここでフェニルおよびベンジルは未置換で あるか、またはそれぞれ独立してアルキル、アルコキシ、ハロゲン、ヒドロキシ 、カルボキシ、カルボアルコキシ、トリフルオロメチル、アミノおよびニトロか ら選択される1〜3個の置換基で置換されうる。 2.R1が水素またはメチルであり、そして 3.R1が水素またはメチルであり、そして 4.R1が水素またはメチルであり、そしてR2が(CH2)1-4-X-(CH2)0-4−フェニル である請求項1記載の化合物。 5.R1が水素またはメチルであり、そしてR2が(CH2)1-S-(CH2)0-4−フェ ニルである請求項1記載の化合物。 6.R1が水素またはメチルであり、そしてR2が7〜11個の炭素の直鎖状または分 枝状アルキルである請求項1記載の化合物。 7.3−アミノメチル−4−シクロヘキシル−酪酸; 3−アミノメチル−5−フェニル−ペンタン酸; 3−アミノメチル−5−ベンジルスルファニル−ペンタン酸; 3−アミノメチル−5−(4−ブロモ−ベンジルスルファニル)−ペンタン 酸; 3−アミノメチル−5−(3,4−ジクロロ−ベンジルスルファニル)−ペンタ ン酸; 5−(4−アミノ−ベンジルオキシ)−3−アミノメチル−ペンタン酸; 3−アミノメチル−5−(4−トリルフルオロメチル−フェニルスルファニ ル)−ペンタン酸; 3−アミノメチル−5−p−トリルスルファニル−ペンタン酸; 3−アミノメチル−4−〔2−(4−クロロ−フェニル)−エチルスルファ ニル〕−酪酸; 3−アミノメチル−4−〔2−(2,4−ジクロロ−フェニル)−エチルスル ファニル〕−酪酸; 3−アミノメチル−4−(4−メチル−ベンジルスルファニル)−酪酸; 3−アミノメチル−4−(4−ブロモ−フェニルスルファニル)−酪酸; 3−アミノメチル−4−(3,4−ジクロロ−ベンジルスルファニル)−酪酸; 3−アミノメチル−4−シクロブチル−酪酸塩酸塩; 3−アミノメチル−4−シクロプロピル−酪酸;および 3−アミノメチル−4−(4−t−ブチル−フェノキシ)−酪酸 から選択される請求項1記載の化合物。 8.治療上有効な量の請求項1記載の化合物および製薬上許容しうる担体を含有 する医薬組成物。 9.治療上有効な量の請求項1記載の化合物をてんかんの治療の必要な哺乳動物 に投与することからなるてんかんの治療法。 10.治療上有効な量の請求項1記載の化合物を失神発作、運動低下症および頭部 傷害の治療の必要な哺乳動物に投与することからなる前記疾患の治療法。 11.治療上有効な量の請求項1記載の化合物を神経変性疾患の治療の必要な哺乳 動物に投与することからなる神経変性疾患の治療法。 12.治療上有効な量の請求項1記載の化合物をうつ病の治療の必要な哺乳動物に 投与することからなるうつ病の治療法。 13.治療上有効な量の請求項1記載の化合物を不安症の治療の必要な哺乳動物に 投与することからなる不安症の治療法。 14.治療上有効な量の請求項1記載の化合物をパニックの治療の必要な哺乳動物 に投与することからなるパニックの治療法。 15.治療上有効な量の請求項1記載の化合物を疼痛の治療の必要な哺乳動物に投 与することからなる疼痛の治療法。 16.治療上有効な量の請求項1記載の化合物を神経病理学的疾患の治療の必要な 哺乳動物に投与することからなる神経病理学的疾患の治療法。 17.治療上有効な量の請求項1記載の化合物を炎症の治療の必要な哺乳動物に投 与することからなる炎症の治療法。 18.治療上有効な量の請求項1記載の化合物を胃腸管損傷の治療の必要な哺乳動 物に投与することからなる胃腸管損傷の治療法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2960196P | 1996-10-23 | 1996-10-23 | |
US60/029,601 | 1996-10-23 | ||
US5990097P | 1997-09-24 | 1997-09-24 | |
US60/059,900 | 1997-09-24 | ||
PCT/US1997/017997 WO1998017627A1 (en) | 1996-10-23 | 1997-10-07 | Substituted gamma aminobutyric acids as pharmaceutical agents |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2002514187A true JP2002514187A (ja) | 2002-05-14 |
Family
ID=26705131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51940498A Ceased JP2002514187A (ja) | 1996-10-23 | 1997-10-07 | 薬剤としての置換γ―アミノ酪酸 |
Country Status (11)
Country | Link |
---|---|
US (1) | US6153650A (ja) |
EP (1) | EP0937032B1 (ja) |
JP (1) | JP2002514187A (ja) |
AT (1) | ATE361909T1 (ja) |
AU (1) | AU733896B2 (ja) |
BR (1) | BR9712651A (ja) |
CA (1) | CA2263663C (ja) |
DE (1) | DE69737719D1 (ja) |
HR (1) | HRP970560B1 (ja) |
NZ (1) | NZ334898A (ja) |
WO (1) | WO1998017627A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001515033A (ja) * | 1997-08-20 | 2001-09-18 | ワーナー−ランバート・カンパニー | 胃腸損傷を防止および治療するためのgaba類縁体 |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6329429B1 (en) | 1997-06-25 | 2001-12-11 | Warner-Lambert Company | Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases |
HRP980342A2 (en) * | 1997-06-25 | 1999-02-28 | Warner Lambert Co | Anti-inflammatory method |
US6127418A (en) * | 1997-08-20 | 2000-10-03 | Warner-Lambert Company | GABA analogs to prevent and treat gastrointestinal damage |
TR200001794T2 (tr) * | 1997-12-16 | 2000-10-23 | Warner-Lambert Company | Farmasötik maddeler olarak yeni aminler |
EP0974351A3 (en) * | 1998-04-24 | 2000-12-13 | Jouveinal | Medicament for preventing and treating gastrointestinal damage |
NZ508490A (en) * | 1998-07-09 | 2003-08-29 | Warner Lambert Co | Use of a combination of a GABA analog and caffeine as an analgesic |
DE69934813T2 (de) * | 1998-10-16 | 2007-10-11 | Warner-Lambert Company Llc | Verwendung von gaba analogen zur herstellung eines arzneimittels zur behandlung von manie und bipolaren erkrankungen |
WO2000031020A1 (en) * | 1998-11-25 | 2000-06-02 | Warner-Lambert Company | Improved gamma amino butyric acid analogs |
FR2791982B1 (fr) * | 1999-04-06 | 2002-12-27 | Inst Nat Sante Rech Med | Inhibiteurs de lta4 hydrolase et leurs applications therapeutiques. |
CA2373210A1 (en) * | 1999-05-26 | 2000-12-07 | Warner-Lambert Company | Fused polycyclic amino acids as pharmaceutical agents |
US6642398B2 (en) | 1999-06-10 | 2003-11-04 | Warner-Lambert Company | Mono-and disubstituted 3-propyl gamma-aminobutyric acids |
DE60041256D1 (de) * | 1999-06-10 | 2009-02-12 | Warner Lambert Co | Mono-substituierte 3-propyl-gamma-aminobuttersäure |
US7164034B2 (en) | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
EP1840117A1 (en) * | 1999-06-10 | 2007-10-03 | Warner-Lambert Company LLC | Mono- and disubstituted 3-propyl gamma-aminobutyric acids |
CA2320556A1 (en) * | 1999-09-29 | 2001-03-29 | Queen's University At Kingston | N,n-dichlorinated omega amino acids and uses thereof |
JP2003528148A (ja) * | 2000-03-28 | 2003-09-24 | デロレンゾ、ロバート・ジェイ | 損傷に際して神経細胞中に形成される新規カルシウム損傷電流の阻害は神経細胞死を抑制する |
AU2002211863A1 (en) | 2000-10-06 | 2002-04-15 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
WO2002032376A2 (en) | 2000-10-06 | 2002-04-25 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
US6620829B2 (en) | 2000-10-17 | 2003-09-16 | Warner-Lambert Company | Method of treating noninflammatory cartilage damage |
AU2002310409C1 (en) | 2001-06-11 | 2008-04-17 | Xenoport, Inc. | Orally administered dosage forms of GABA analog prodrugs having reduced toxicity |
US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
EP1412324A4 (en) | 2001-06-11 | 2004-09-29 | Xenoport Inc | AMINO ACID CONJUGATES THAT RESULT IN GABA ANALOGA LASTING SYSTEMIC CONCENTRATIONS |
DE10203122A1 (de) * | 2002-01-25 | 2003-07-31 | Gruenenthal Gmbh | Verfahren zur Herstellung von substituierten Acrylsäureestern bzw. deren Einsatz zur Herstellung von substituierten gamma-Aminosäuren |
IL162028A0 (en) * | 2002-01-31 | 2005-11-20 | Warner Lambert Co | Alpha 2 delta ligands to treat tinnitus |
US6927036B2 (en) | 2002-02-19 | 2005-08-09 | Xero Port, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
AU2003222033A1 (en) * | 2002-03-20 | 2003-10-08 | Xenoport | Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof |
NI200300043A (es) | 2002-03-28 | 2003-11-05 | Warner Lambert Co | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA. |
AU2003243180A1 (en) | 2002-05-17 | 2003-12-12 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
BR0312240A (pt) * | 2002-06-27 | 2005-04-12 | Warner Lambert Co | Método de tratamento do distúrbio por déficit de atenção com hiperatividade |
WO2004052360A1 (en) | 2002-12-11 | 2004-06-24 | Xenoport, Inc. | Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof |
AU2003286300A1 (en) * | 2002-12-13 | 2004-07-09 | Warner-Lambert Company Llc | Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders |
CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
ES2341240T3 (es) | 2002-12-13 | 2010-06-17 | Warner-Lambert Company Llc | Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior. |
KR20050085636A (ko) | 2002-12-13 | 2005-08-29 | 워너-램버트 캄파니 엘엘씨 | 섬유근육통 및 기타 질환의 치료를 위한 프레가발린 유도체 |
EP1670451A4 (en) | 2003-09-11 | 2009-10-21 | Xenoport Inc | TREATMENT AND / OR PREVENTION OF URINARY INCONTINENCE AND PROMOTERS OF GABA ANALOGS |
RU2320369C2 (ru) | 2003-09-12 | 2008-03-27 | Пфайзер Инк. | Комбинации, содержащие альфа-2-дельта лиганды и ингибиторы обратного захвата серотонина/норадреналина |
US8114909B2 (en) | 2003-09-17 | 2012-02-14 | Xenoport, Inc. | Treating or preventing restless legs syndrome using prodrugs of GABA analogs |
JP2007506729A (ja) | 2003-09-25 | 2007-03-22 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | α2δタンパク質に親和性を有するアミノ酸のプロドラッグ |
AU2004276072A1 (en) * | 2003-09-25 | 2005-04-07 | Warner-Lambert Company Llc | Amino acids with affinity for the alpha2delta-protein |
NZ546381A (en) | 2003-10-14 | 2010-01-29 | Xenoport Inc | Crystalline form of gamma-aminobutyric acid analog |
PL1691811T3 (pl) | 2003-12-11 | 2014-12-31 | Sunovion Pharmaceuticals Inc | Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji |
EP1811986B1 (en) | 2004-11-04 | 2014-03-26 | XenoPort, Inc. | Gabapentin prodrug sustained release oral dosage forms |
MX2009006575A (es) | 2006-12-22 | 2009-07-02 | Recordati Ireland Ltd | Terapia de combinacion de trastornos del tracto urinario inferior con ligandos a2d y farmacos anti-inflamatorios no esteroidales (nsaids). |
WO2009094577A2 (en) | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
US7872046B2 (en) | 2008-01-25 | 2011-01-18 | Xenoport, Inc. | Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use |
CA2706575C (en) | 2008-01-25 | 2015-07-14 | Xenoport, Inc. | Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs |
CN105330603A (zh) | 2008-10-08 | 2016-02-17 | 凯飞药业公司 | Gaba偶联物及其使用方法 |
US9066853B2 (en) | 2013-01-15 | 2015-06-30 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable fiber |
AU2014209028C1 (en) | 2013-01-28 | 2019-08-29 | Hector L. Lopez | Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor |
CN107857710A (zh) * | 2017-11-23 | 2018-03-30 | 河南师范大学 | 一种抗癫痫药普瑞巴林的制备方法 |
CA3099775A1 (en) | 2018-05-14 | 2019-11-21 | Xgene Pharmaceutical Inc. | Process for making 1-(acyloxy)-alkyl-carabmate drug conjugates of naproxen and pregabalin |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1385846A (en) * | 1973-05-18 | 1975-03-05 | Le G Venny Ped I Im A I Gertse | Chlorohydrate of beta-phenyl-ypsilon-amino butyric acid and process for producing same |
US4087544A (en) * | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
ZA902661B (en) * | 1989-04-10 | 1991-01-30 | Schering Corp | Mercapto-acyl amino acids |
ATE117988T1 (de) * | 1990-05-17 | 1995-02-15 | Schering Corp | Disulfidderivate von mercapto-acyl-aminsäuren. |
AU9137091A (en) * | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
ES2165857T3 (es) * | 1992-05-20 | 2002-04-01 | Univ Northwestern | Analogos de gaba y acido l-glutamico para el tratamiento de trastornos del sistema nervioso central. |
IL109397A0 (en) * | 1993-04-28 | 1994-07-31 | Schering Ag | Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
DE4439492A1 (de) * | 1994-10-25 | 1996-05-02 | Schering Ag | Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln |
DE4439493A1 (de) * | 1994-10-25 | 1996-05-02 | Schering Ag | Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln |
-
1997
- 1997-10-07 AT AT97945516T patent/ATE361909T1/de not_active IP Right Cessation
- 1997-10-07 US US09/254,093 patent/US6153650A/en not_active Expired - Fee Related
- 1997-10-07 WO PCT/US1997/017997 patent/WO1998017627A1/en active IP Right Grant
- 1997-10-07 EP EP97945516A patent/EP0937032B1/en not_active Expired - Lifetime
- 1997-10-07 JP JP51940498A patent/JP2002514187A/ja not_active Ceased
- 1997-10-07 AU AU46697/97A patent/AU733896B2/en not_active Ceased
- 1997-10-07 CA CA002263663A patent/CA2263663C/en not_active Expired - Fee Related
- 1997-10-07 NZ NZ334898A patent/NZ334898A/xx unknown
- 1997-10-07 DE DE69737719T patent/DE69737719D1/de not_active Expired - Lifetime
- 1997-10-07 BR BR9712651-9A patent/BR9712651A/pt active Search and Examination
- 1997-10-23 HR HR970560A patent/HRP970560B1/xx not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001515033A (ja) * | 1997-08-20 | 2001-09-18 | ワーナー−ランバート・カンパニー | 胃腸損傷を防止および治療するためのgaba類縁体 |
Also Published As
Publication number | Publication date |
---|---|
HRP970560B1 (en) | 2003-02-28 |
HRP970560A2 (en) | 1998-08-31 |
AU733896B2 (en) | 2001-05-31 |
CA2263663A1 (en) | 1998-04-30 |
WO1998017627A1 (en) | 1998-04-30 |
NZ334898A (en) | 2000-09-29 |
ATE361909T1 (de) | 2007-06-15 |
US6153650A (en) | 2000-11-28 |
EP0937032B1 (en) | 2007-05-09 |
DE69737719D1 (de) | 2007-06-21 |
BR9712651A (pt) | 1999-10-26 |
CA2263663C (en) | 2006-05-30 |
EP0937032A1 (en) | 1999-08-25 |
AU4669797A (en) | 1998-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002514187A (ja) | 薬剤としての置換γ―アミノ酪酸 | |
EP0888286B1 (en) | Novel substituted cyclic amino acids as pharmaceutical agents | |
EP0888325B1 (en) | Novel cyclic amino acids as pharmaceutical agents | |
US6245801B1 (en) | Branched alkyl pyrrolidine-3-carboxylic acids | |
US7122678B2 (en) | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | |
JP2002516312A (ja) | カルシウムチャンネルのα2δサブユニットに対する親和性を有する立体配座的に制約されたアミノ酸化合物 | |
JP2002508361A (ja) | ((シクロ)アルキル置換)−γ−アミノ酪酸誘導体(=GABA類似体)、それらの製造および神経学的疾患の治療における使用 | |
JP2000506862A (ja) | 医薬としての新規な架橋環状アミノ酸 | |
JP2003502308A (ja) | モノ−およびジ置換3−プロピルガンマ−アミノ酪酸 | |
EP1185524B1 (en) | 3-heteroarylalkyl substituted gaba analogs | |
US6833385B2 (en) | 3-heteroarylalkyl substituted GABA analogs | |
MXPA99001776A (en) | Substituted gamma aminobutyric acids as pharmaceutical agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060613 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060913 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061030 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20070205 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070306 |